公开(公告)号：US10912766B2

公开(公告)日：2021-02-09

申请号：US16653297

申请日：2019-10-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Tasir Shamsul Haque ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Shoshana L. Posy ,  Ramesh Kumar Sistla ,  Subramanya Hegde ,  Anupama Kandhi Ramachandra Reddy

IPC: A61K31/4196 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D249/00 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20180370956A1

公开(公告)日：2018-12-27

申请号：US16009389

申请日：2018-06-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Rajeev S. BHIDE ,  John V. Duncia ,  John Hynes ,  Satheesh K. Nair ,  William J. Pitts ,  Sreekantha Ratna Kumar ,  Daniel S. Gardner ,  Natesan Murugesan ,  Venkatram Reddy Paidi ,  Joseph B. Santella ,  Ramesh Kumar Sistla ,  Hong Wu

IPC: C07D407/14 ,  C07D405/14 ,  C07D405/12 ,  C07D213/74 ,  C07D401/14 ,  C07D417/14 ,  C07D401/12

Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

公开(公告)号：US10071079B2

公开(公告)日：2018-09-11

申请号：US15635055

申请日：2017-06-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Ramesh Kumar Sistla

IPC: C07D471/04 ,  A61K31/4196 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D249/00

CPC classification number: A61K31/4196 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D249/00 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20180079712A1

公开(公告)日：2018-03-22

申请号：US15564146

申请日：2016-04-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Audris Huang ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: C07C229/42 ,  C07C275/42 ,  C07D295/155 ,  C07D239/47 ,  C07D277/64 ,  C07D335/02 ,  C07D409/12 ,  C07D309/14 ,  C07D405/12 ,  C07D211/14 ,  C07D401/12 ,  C07D317/46 ,  C07D239/34 ,  C07D413/12 ,  C07D265/30 ,  C07C233/81 ,  C07D405/14 ,  C07D207/12 ,  C07D487/08 ,  C07D487/04 ,  C07D471/08 ,  C07D265/36 ,  C07D413/14

Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

公开(公告)号：US20180000790A1

公开(公告)日：2018-01-04

申请号：US15635055

申请日：2017-06-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Tasir Shamsul Haque ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Shoshana L. Posy ,  Ramesh Kumar Sistla ,  Subramaya Hegde ,  Anupama Ramachandra

IPC: A61K31/4196 ,  A61K45/06 ,  A61K31/4427 ,  C07D471/04 ,  A61K31/437

CPC classification number: A61K31/4196 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D249/00 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20160289171A1

公开(公告)日：2016-10-06

申请号：US15088211

申请日：2016-04-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Emily Charlotte Cherney ,  Weiwei Guo ,  Audris Huang ,  Jay A. Markwalder ,  Steven P. Seitz ,  Weifang Shan ,  David K. Williams ,  Natesan Murugesan ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Ramesh Kumar Sistla ,  Srinivas Cheruku ,  Srinivasan Thangathirupathy ,  Yadagiri Kanyaboina ,  Nagalakshmi Pulicharla

IPC: C07C229/42 ,  A61K31/196 ,  C07D239/47 ,  A61K31/505 ,  C07C255/58 ,  A61K31/277 ,  C07C275/40 ,  A61K31/17 ,  C07D295/155 ,  A61K31/5375 ,  C07D277/64 ,  A61K31/428 ,  C07D335/02 ,  A61K31/382 ,  C07D409/12 ,  A61K31/506 ,  C07D309/04 ,  A61K31/351 ,  C07D405/12 ,  C07D211/14 ,  A61K31/445 ,  C07D401/12 ,  C07D413/12 ,  A61K31/5377 ,  C07D405/14 ,  C07D417/12 ,  C07D487/04 ,  A61K31/519 ,  A61K31/501 ,  C07D471/04 ,  A61K31/437 ,  C07D205/04 ,  A61K31/397 ,  A61K31/538 ,  C07D265/36 ,  A61K39/395

CPC classification number: C07C275/40 ,  A61K31/17 ,  A61K31/196 ,  A61K31/277 ,  A61K31/351 ,  A61K31/382 ,  A61K31/397 ,  A61K31/428 ,  A61K31/437 ,  A61K31/445 ,  A61K31/501 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/538 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07C229/42 ,  C07C233/81 ,  C07C235/38 ,  C07C235/56 ,  C07C255/57 ,  C07C255/58 ,  C07C275/30 ,  C07C275/42 ,  C07D205/04 ,  C07D207/08 ,  C07D207/12 ,  C07D211/08 ,  C07D211/14 ,  C07D239/34 ,  C07D239/47 ,  C07D265/30 ,  C07D265/36 ,  C07D277/64 ,  C07D295/155 ,  C07D307/22 ,  C07D309/04 ,  C07D309/14 ,  C07D317/46 ,  C07D335/02 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/08

Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Abstract translation: 公开了调节或抑制吲哚胺2,3-双加氧酶（IDO）的酶活性的化合物，含有所述化合物的药物组合物和治疗增殖性疾病如癌症，病毒感染和/或炎症性疾病的方法，其利用 发明。

公开(公告)号：US12059420B2

公开(公告)日：2024-08-13

申请号：US17261954

申请日：2019-07-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： James Aaron Balog ,  Jay A. Markwalder ,  Weifang Shan ,  David K. Williams ,  Susheel Jethanand Nara ,  Saumya Roy ,  Soodamani Thangavel ,  Srinivas Cheruku ,  Ramesh Kumar Sistla

IPC: A61K31/506 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/519 ,  A61K31/5377 ,  A61K39/395 ,  C07D213/74 ,  C07D213/75 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D487/04

CPC classification number: A61K31/506 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/501 ,  A61K31/519 ,  A61K31/5377 ,  A61K39/3955 ,  C07D213/74 ,  C07D213/75 ,  C07D401/14 ,  C07D403/10 ,  C07D403/14 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/10 ,  C07D417/14 ,  C07D487/04

Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.

公开(公告)号：USRE49893E1

公开(公告)日：2024-04-02

申请号：US17584155

申请日：2022-01-25

Applicant: Bristol-Myers Squibb Company

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Tasir Shamsul Hague ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Shoshana L. Posy ,  Ramesh Kumar Sistla ,  Subramanya Hegde ,  Anupama Kandhi Ramachandra Reddy

IPC: A61K31/4196 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D249/00 ,  C07D471/04

CPC classification number: A61K31/4196 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D249/00 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I)




or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20230098244A1

公开(公告)日：2023-03-30

申请号：US17699944

申请日：2022-03-21

Applicant: Bristol-Myers Squibb Company

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  Trevor C. Sherwood ,  John L. Gilmore ,  Tsair Shamsul Haque ,  Brian K. Whiteley ,  David R. Tortolani ,  Shoshana L. Posy ,  John E. Macor ,  Louis J. Lombardo ,  Ramesh Kumar Sistla ,  Anupama Kandhi Ramachandra Reddy ,  Subramanya Hegde ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar

IPC: C07D498/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04

Abstract: Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20200038374A1

公开(公告)日：2020-02-06

申请号：US16653297

申请日：2019-10-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Tasir Shamsul Haque ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Shoshana L. Posy ,  Ramesh Kumar Sistla ,  Subramanya Hegde ,  Anupama Kandhi Ramachandra Reddy

IPC: A61K31/4196 ,  C07D249/00 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.